Biotricity FY26 net loss narrows to $3.13 million; revenue rises 16% to $16 million
BTCY•Fiscal 2026 results improve on higher revenue and margins
- Biotricity reported fiscal 2026 net loss attributable to common stockholders of $3.13 million, narrowing from $11.94 million a year earlier.
- Revenue rose 16% to $16 million, lifting operating results to operating income of $1.69 million from an operating loss of $2.45 million.
- Gross margin improved 4.4 percentage points to 81%, reflecting a higher mix of technology fees, which totaled $14.44 million.
- Selling, general and administrative expense fell to $8.49 million from $10.86 million, while research and development expense increased to $2.76 million from $2.16 million.
- Cash and cash equivalents were $149,789 at March 31, 2026, with a working capital deficit of $31.3 million.
Related News
Writers Guild sues to block Paramount deal, saying it would hurt writers
PSKY•
AutoZone SVP Finance Grace Orians Sharpley files initial beneficial ownership statement
AZO•
